UroGen Pharma
(NASDAQ) URGN
UroGen Pharma Financials at a Glance
Market Cap
$899.65M
Revenue (TTM)
$109.79M
Net Income (TTM)
$153.49M
EPS (TTM)
$-3.21
P/E Ratio
-5.76
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Price
$18.64
Volume
17,756
Open
$18.40
Price
$18.64
Volume
17,756
Open
$18.40
Previous Close
$18.64
Daily Range
$18.30 - $18.88
52-Week Range
$3.42 - $30.00
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Price
$18.64
Volume
17,756
Open
$18.40
Previous Close
$18.64
Daily Range
$18.30 - $18.88
52-Week Range
$3.42 - $30.00
URGN News
URGN: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout UroGen Pharma
Industry
Biotechnology
Sector
Health CareEmployees
291
CEO
Elizabeth Barrett, MBA
Website
www.urogen.comHeadquarters
Princeton, NJ 08540, US
URGN Financials
Key Financial Metrics (TTM)
Gross Margin
89%
Operating Margin
-1%
Net Income Margin
-1%
Return on Equity
0%
Return on Capital
-81%
Return on Assets
-77%
Earnings Yield
-17.36%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$899.65M
Shares Outstanding
48.68M
Volume
17.76K
Short Interest
0.00%
Avg. Volume
770.93K
Financials (TTM)
Gross Profit
$97.34M
Operating Income
$124.86M
EBITDA
$135.66M
Operating Cash Flow
$162.44M
Capital Expenditure
$289.00K
Free Cash Flow
$162.73M
Cash & ST Invst.
$120.46M
Total Debt
$128.33M
UroGen Pharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$37.84M
+54.0%
Gross Profit
$34.55M
+56.4%
Gross Margin
91.31%
N/A
Market Cap
$899.65M
N/A
Market Cap/Employee
$3.84M
N/A
Employees
234
N/A
Net Income
$26.36M
+29.7%
EBITDA
$22.19M
+16.2%
Quarterly Fundamentals
Net Cash
$7.88M
-107.0%
Accounts Receivable
$33.08M
+62.9%
Inventory
$16.46M
+78.4%
Long Term Debt
$128.33M
+4.0%
Short Term Debt
$0.00
N/A
Return on Assets
-76.57%
N/A
Return on Invested Capital
-81.06%
N/A
Free Cash Flow
$38.34M
-179.2%
Operating Cash Flow
$38.33M
-181.4%